AU641942B2 - The use of thioredoxin in the treatment of malignantly transformed cells in animals and man - Google Patents

The use of thioredoxin in the treatment of malignantly transformed cells in animals and man

Info

Publication number
AU641942B2
AU641942B2 AU64336/90A AU6433690A AU641942B2 AU 641942 B2 AU641942 B2 AU 641942B2 AU 64336/90 A AU64336/90 A AU 64336/90A AU 6433690 A AU6433690 A AU 6433690A AU 641942 B2 AU641942 B2 AU 641942B2
Authority
AU
Australia
Prior art keywords
thioredoxin
treatment
factor
cells
transformed cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64336/90A
Other languages
English (en)
Other versions
AU6433690A (en
Inventor
Anders Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of AU6433690A publication Critical patent/AU6433690A/en
Application granted granted Critical
Publication of AU641942B2 publication Critical patent/AU641942B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU64336/90A 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man Ceased AU641942B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903003 1989-09-12
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use

Publications (2)

Publication Number Publication Date
AU6433690A AU6433690A (en) 1991-04-18
AU641942B2 true AU641942B2 (en) 1993-10-07

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64336/90A Ceased AU641942B2 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man

Country Status (12)

Country Link
EP (1) EP0489113A1 (ja)
JP (1) JPH05500216A (ja)
AU (1) AU641942B2 (ja)
CA (1) CA2065454A1 (ja)
DD (1) DD298056A5 (ja)
FI (1) FI921058A0 (ja)
GR (1) GR1001151B (ja)
HU (1) HUT62932A (ja)
IE (1) IE903233A1 (ja)
PT (1) PT95284A (ja)
SE (1) SE8903003D0 (ja)
WO (1) WO1991004320A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO1998000160A1 (en) * 1996-06-28 1998-01-08 Nat Jewish Ct Immun & Respirat USE OF THIOREDOXIN-LIKE MOLECULES FOR INDUCTION OF MnSOD TO TREAT OXIDATIVE DAMAGE
WO1998024472A1 (en) * 1996-12-06 1998-06-11 Garth Powis Uses of thioredoxin
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
EP1049772A1 (en) 1998-01-30 2000-11-08 Genesense Technologies, Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1332212A2 (en) * 2000-08-25 2003-08-06 Curagen Corporation Proteins and nucleic acids encoding same
JP2006513147A (ja) 2002-09-10 2006-04-20 ナショナル ジューイッシュ メディカル アンド リサーチ センター 粘液または痰の液化のための生成物および処理
MX2015013040A (es) 2013-03-15 2016-05-24 Orpro Therapeutics Inc Producto y proceso para normalización de la viscosidad del moco.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (ja) * 1987-06-12 1997-07-23 味の素株式会社 ヒトａｄｆをコードする遺伝子

Also Published As

Publication number Publication date
HU9200821D0 (en) 1992-05-28
IE903233A1 (en) 1991-03-27
GR900100679A (en) 1992-01-20
JPH05500216A (ja) 1993-01-21
SE8903003D0 (sv) 1989-09-12
AU6433690A (en) 1991-04-18
DD298056A5 (de) 1992-02-06
HUT62932A (en) 1993-06-28
FI921058A0 (fi) 1992-03-11
CA2065454A1 (en) 1991-03-13
EP0489113A1 (en) 1992-06-10
GR1001151B (el) 1993-05-24
WO1991004320A1 (en) 1991-04-04
PT95284A (pt) 1991-08-14

Similar Documents

Publication Publication Date Title
Defrance et al. Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes.
Rosen et al. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin
AU641942B2 (en) The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
Lotz et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.
Schmouder et al. In vitro and in vivo interleukin-8 production in human renal cortical epithelia
Defrance et al. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.
DeKruyff et al. Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor.
Schluesener Transforming growth factors type β1 and β2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-γ and tumor necrosis factor-α
Schmitt et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma.
Bertagnolli et al. IL-12 augments antigen-dependent proliferation of activated T lymphocytes.
Ceuppens et al. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal.
Tosato et al. Interferon-beta 2/interleukin 6 is a co-stimulant for human T lymphocytes.
Petit-Frere et al. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes.
Desai et al. IL-12 receptor. II. Distribution and regulation of receptor expression.
Gardella et al. Interleukin-18 synthesis and secretion by dendritic cells are modulated by interaction with antigen-specific T cells
Defrance et al. Human interferon-gamma acts as a B cell growth factor in the anti-IgM antibody co-stimulatory assay but has no direct B cell differentiation activity.
JPH09510444A (ja) 自己免疫疾患の治療におけるｉｌ−１２およびｉｌ−１２アンタゴニストの使用
Ke et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Te Velde et al. IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes.
AU621046B2 (en) Method for therapy of leukemias and certain other malignancies
Grimm et al. The IL‐2 mediated amplification of cellular cytotoxicity
Moqattash et al. Leukemia cells and the cytokine network
Sleasman et al. The role of functionally distinct helper T lymphocyte subpopulations in the inductionof human B cell differentiation
Jurado et al. The immunomodulatory effects of interferon-gamma on mature B-lymphocyte responses